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Abstract
Cost-effectiveness analysis (CEA) is an increasingly appealing tool for evaluating and comparing 
health-related interventions in resource-limited settings. The goal is to inform decision-makers 
regarding the health benefits and associated costs of alternative interventions, helping guide 
allocation of limited resources by prioritizing interventions that offer the most health for the least 
money. Although only one component of a more complex decision-making process, CEAs 
influence the distribution of healthcare resources, directly influencing morbidity and mortality for 
the world’s most vulnerable populations. However, CEA-associated measures are frequently 
setting-specific valuations, and CEA outcomes may violate ethical principles of equity and 
distributive justice. We examine the assumptions and analytical tools used in CEAs that may 
conflict with societal values. We then evaluate contextual features unique to resource-limited 
settings, including the source of health-state utilities and disability weights; implications of CEA 
thresholds in light of economic uncertainty; and the role of external donors. Finally, we explore 
opportunities to help align interpretation of CEA outcomes with values and budgetary constraints 
in resource-limited settings. The ethical implications of CEAs in resource-limited settings are vast. 
It is imperative that CEA outcome summary measures and implementation thresholds adequately 
reflect societal values and ethical priorities in resource-limited settings.
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Introduction
Cost-effectiveness analyses (CEA) have become an increasingly appealing and powerful tool 
for evaluating and comparing alternative health-related interventions (Dhaliwal, Duflo, 
Glennerster, & Tulloch, 2011; Eichler, Kong, Gerth, Mavros, & Jonsson, 2004; Jamison, 
Breman, & Measham, 2006). The purpose of CEAs is to provide information to decision-
makers on the efficiency of different interventions for achieving a specific health outcome, 
helping guide allocation of finite resources and prioritize interventions that offer the most 
health for the least money (Gold, Siegel, Russell, & Weinstein, 1996; Jamison, Breman, 
ARMeasham, & et. al., 2006; WHO, 2005). The ethical complexity of incorporating costs 
into clinical decisions or healthcare policy have been explored in resource-rich settings 
(Brock, 2004; Pinkerton, Johnson-Masotti, Derse, & Layde, 2002; Williams, 1992); CEA 
outcomes may violate ethical principles of equity and distributive justice (Braveman & 
Gruskin, 2003; Mshana et al., 2007; Rawls, 1971; Whitehead, 1992). Despite growing 
interest in CEAs among researchers and policymakers (Baltussen, 2006), given poor 
baseline health, economic instability, and the role of external donors in driving allocation of 
scarce resources, the ethical incongruences of CEAs with societal values may be especially 
pertinent in resource-limited settings.
Ethics, broadly, are the values or ideals that we perceive as an appropriate standard or code 
to govern behavior and actions. Equity is one such value, emphasizing the quality of fairness 
within this larger code of ethics; distributive justice refers to the equitable distribution of 
scarce resources. Although the expectation is not that policymakers will make healthcare 
resource-allocation decisions based solely on the outcome of a CEA model, it is imperative 
that we appreciate the potential conflict between CEA outcomes and societal values as these 
models are incorporated into decision-making processes. Failure to do so may result in 
distribution of scarce dollars towards interventions that do not reflect priorities of 
implementing partners.
In this paper, we briefly review the basics of CEA modeling and its intended use. We then 
examine the assumptions and analytical tools used in CEAs that may conflict with societal 
values, including how currently applied CEA metrics may clash with values of equity and 
distributive justice. We then evaluate contextual features unique to resource-limited settings 
including the universality of health state utility or disability estimates and the challenge of 
establishing cost-effectiveness thresholds in light of economic uncertainty and given the role 
of external donors. Finally, we evaluate methodological opportunities to help align 
interpretation of CEA outcomes with objectives, values, and budgetary constraints for 
policymakers in resource-limited settings.
CEA Basics
CEAs are a form of economic analysis in which interventions (e.g. drugs, devices, screening 
programs) are compared to each other in terms of both costs and outcomes. The primary 
outcomes for CEAs capture benefits incurred by interventions in terms of both health 
quantity (years of life) and health quality gains (reduced morbidity). The traditional metric 
of evaluation used in CEAs in resource-rich settings is the quality-adjusted life year (QALY) 
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–a composite measure that represents disease or disability burden associated with a given 
health state, ranging from 0 (death equivalent) to 1 (perfect health) (Drummond, Sculpher, 
Torrance, O’Brien, & Stoddart, 2005). Conversely, the disability-adjusted life year (DALY) 
is the preferred metric for use in resource-limited settings as it is based on disability weights 
derived from surveys administered internationally by the Global Burden of Disease, Injuries, 
and Risk Factors Study (GBD) (Salomon et al., 2012). Disability weights, quantified on a 
scale from 0 (full health) to 1 (death), are used to calculate years of life living with disability 
and combine with years of life lost due to disability to generate the DALY estimate, 
accounting for both disability and mortality (WHO, 2005).
Whether generating QALY or DALY estimates, the final summary measure in CEAs is 
frequently an incremental cost-effectiveness ratio (ICER), representing comparative benefits 
and costs between two comparators by linking survival, health-related quality of life, and 
resource consumption into a single unit. For the purposes of prioritizing interventions, 
ICERs can be compared to one another or to an a priori defined threshold of cost-
effectiveness (WHO, 2005). Although just one component of a complicated decision-making 
process, CEA outcomes can be used to help justify expansion or elimination of health 
programs, with the overarching goal of optimizing the allocation of finite resources targeted 
towards population health improvement.
The setting-specific quality of CEA metrics
The “quality” component of the QALY is derived from utility surveys conducted almost 
exclusively in resource-rich settings. Truncated attainable health (i.e., persons not able to 
reach “perfect” health) and poorer baseline health complicate the extension of utility weights 
derived from resource-rich populations to resource-limited settings. If health status utility is 
considered only as it relates to attainable health, then health utility will necessarily differ 
between resource-rich and resource-limited settings (Bleichrodt, Herrero, & Pinto, 2002). 
Expectations of health and the value associated with health gains are different between 
resource-rich and resource-limited settings (Fryback & Lawrence, 1997; Ottersen, Mbilinyi, 
Maestad, & Norheim, 2008). Use of a common utility weight that does not consider 
differential life expectancy and health expectations may inappropriately categorize the utility 
decrement of an illness based on resource-rich setting values, distorting the potential benefit 
of interventions when applied to resource-limited settings (Fryback & Lawrence, 1997).
The DALY is able to avoid some of these biases and is thus preferred over the QALY for use 
in resource-limited contexts. Nonetheless, the DALY is still subject to setting-specific 
limitations. The ordinal rank of disability weights from the GBD may be relatively stable 
across countries (Salomon et al., 2012; Ustun et al., 1999), but the universality of their 
specific valuations has been debated (James & Foster, 1999; Jelsma, Chivaura, Mhundwa, 
De Weerdt, & de Cock, 2000). How an individual experiences disability depends on societal 
accommodation of persons with that disability such that functional status and social 
participation of two people with the same diagnosis may vary widely in different contexts 
(Mont, 2007). Setting-specific utility and disability weights are critical in order for CEA 
outcomes to accurately reflect health status values.
Rutstein et al. Page 3
Glob Public Health. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Concerns of Equity and Distributive Justice in CEA: is the QALY/DALY to 
blame?
Prioritization of health interventions based on DALY aversion may be at odds with societal 
values of equity. CEA-guided resource allocation relies on the assumption that resources 
should be distributed to maximize overall population health (Making choices in health: 
WHO Guide to Cost-effectiveness Analysis, 2003). This utilitarian approach of maximizing 
quality gains and averting disability has inherent tensions with the ethical principles of 
equity and distributive justice; maximizing population health could neglect particular 
societal preferences related to distribution of health benefits (Bitton & Eyal, 2011; Bobinac, 
van Exel, Rutten, & Brouwer, 2012; Mshana et al., 2007; Ottersen et al., 2008; Ubel, DeKay, 
Baron, & Asch, 1996; Ubel et al., 2000). Although derived from inverted scales of health 
utility and disability, the QALY and DALY may suffer similar ethical pitfalls in both 
resource-rich and resource-limited settings such that discussion of equity and distributive 
justice in CEAs can apply broadly to analyses based on either metric (Brock, 2004).
One distinction between the QALY and DALY is rooted in the ability of the DALY to apply 
age-based weights to life-years of similar quality (Murray & Lopez, 1996). By over-valuing 
the socially productive life-years, the age-weighted DALY has been criticized for assigning 
value to individuals for the societal and economic gains of others rather than for individual 
health benefit (Brock, 2004). Others maintain that age-weighting is necessarily equitable 
because every person has the potential to live through all ages, thereby leveling the weights 
over an individual lifetime and permitting age-based prioritization (Murray & Lopez, 1996; 
Tsuchiya, 1999). According to policymakers in many resource-limited settings, age, along 
with other considerations such as severity of disease, is often the main criterion when 
determining resource distribution (Baltussen, Stolk, Chisholm, & Aikins, 2006; Kapiriri, 
Arnesen, & Norheim, 2004; Kapiriri & Norheim, 2004; Ottersen et al., 2008).
While a distributive justice framework prioritizes resource allocation to the sickest persons 
in a society, irrespective of the likelihood and magnitude of expected improvement, a DALY-
aversion approach prioritizes the sickest persons only if they are likely to achieve the 
greatest health gains (Nord, 2015; Ubel et al., 2000). For example, in terms of CEA calculus, 
a health intervention that provides disability reduction of 0.4 to 0 is equivalent to one that 
provides reduction from 0.9 to 0.5; both interventions reduce disability by 0.4. However, an 
egalitarian approach would prioritize the program that improved the status of a very sick 
person (disability weight 0.9 at baseline) to moderate health, over the program that improved 
a moderately sick person (disability weight 0.4 at baseline) to perfect health. This 
‘realization of potential’ or ‘fair chances’ argument advocates that permanently disabled or 
chronically ill persons should have a fair chance of receiving health-improving interventions 
despite having truncated attainable health (Nord & Johansen, 2014; Nord, Pinto, Richardson, 
Menzel, & Ubel, 1999; Williams, 1997). Importantly, not all scenarios offer identical health 
gains; the scenario in which the choice is between disability reduction of 0.4 to 0 versus 0.9 
to 0.6 complicates the fair chances argument. Selecting the intervention that prioritizes the 
very sick would do less good, thereby violating ethical principles of beneficence, but 
selecting the larger disability reduction for the healthier person violates principles of equity. 
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This conflict exemplifies that, ultimately, the sole objective of averting DALYs may not 
align with a society’s valuation of the severely ill, or persons with chronic illness or 
disability (Pinkerton et al., 2002).
Analyses based on utility and disability weights, typically developed by health professionals 
and the non-disabled, may undervalue the years of life of the disabled or chronically ill and 
favor interventions that prevent or cure illness rather than enhance the lives of persons living 
with disabilities (Brock, 2004; Fox Rushby, 2002; Mont, 2007). A systematic review of 
HIV/AIDS interventions in Africa concluded that programs focused on preventing incident 
HIV infection are considerably more cost-effective than treatment and care for the already 
infected (Creese, Floyd, Alban, & Guinness, 2002). However, strictly utilitarian and human 
capital approaches to cost-effectiveness that ignore pre-existing heath inequities, disease-
specific stigmatization, and socio-political priorities may perpetuate health disparities by 
valuing healthy privileged persons with higher social capital over already sick or 
disadvantaged groups (Pinkerton et al., 2002). This ethical consideration should demand 
particular attention when evaluating interventions in resource-limited settings.
Demonstrating the conflict with accepted societal norms, district and regional health 
planners in Tanzania prioritized interventions that supported persons with the lowest life 
expectancy over interventions that maximized the number of life-years (Ottersen et al., 
2008). The strength of a society’s concern for disease severity, or ‘vertical equity’, has been 
studied empirically by asking subjects how much more utility would have to be gained (or 
disability averted) for an intervention targeted at healthier individuals to be preferred over an 
intervention targeted at sicker individuals (Dolan, 1998; Nord, 2015; Nord & Johansen, 
2014). Representing the point at which a society would permit less cost-effective 
interventions that address diseases of greater severity, this higher utility value demonstrates 
the conceptual divergence between CEA outcomes and the objective of distributive justice – 
a concept that must be considered when interpreting CEA models.
The ethically indifferent CEA thresholds
Cost-effectiveness thresholds are wrought with ethical conflicts. Thresholds define a dollar-
per-QALY-gained or dollar-per-DALY-averted (i.e., ICER) cutoff of acceptability. Selecting 
an appropriate and defensible CEA threshold is challenging and cutoffs are often chosen 
arbitrarily (Hirth, Chernew, Miller, Fendrick, & Weissert, 2000). Although failure to achieve 
a cutoff does not automatically dismiss a program, understanding the limitations of how 
thresholds are established is relevant when incorporating the CEA outcome into the 
resource-allocation decision process.
Even if an intervention meets a cost-effectiveness threshold, the ICER value does not 
necessarily reflect the bottom-line expense associated with implementation; a cost-effective 
intervention for a highly prevalent disease could exceed the entire budget, whereas a less 
cost-effective intervention that exclusively targets a subpopulation (i.e., pregnant women) 
may be financially feasible. Ultimately, choosing the more cost-effective intervention may 
not be compatible with health budgets (Birch & Gafni, 2006; Sendi & Briggs, 2001).
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Decision rules using willingness to pay (WTP) per QALY/DALY may provide additional 
flexibility compared to defining a single ICER value threshold. WTP allows decision-makers 
to consider the decision context and incorporate societal value-of-life preferences. WTP 
assigns a monetary value to a package of health goods or benefits. Determining the WTP is 
frequently based on preference elicitation methods that employ hypothetical scenarios asked 
of the general population or policymakers. Unfortunately, much like the health state utilities 
and disability weights, preference elicitation exercises are often limited to surveys from 
resource-rich settings and may not reflect WTP in resource-limited settings.(Shillcutt, 
Walker, Goodman, & Mills, 2009)
The wealth of the surveyed population substantially influences the projected WTP. WTP 
increases with wealth, but this increase is not proportional, highlighting complexities in 
preference formation (Dolan, Metcalfe, Munro, & Christensen, 2008; Shillcutt et al., 2009). 
In fact, the value of health is often positively correlated with the current state of health 
within a population (King, Tsevat, & Roberts, 2004). Together, these observations imply that 
in worse states of health, commonly experienced by populations in resource-limited settings, 
health may hold less value than in wealthier and healthier countries. Essentially, this 
relationship produces a lower WTP per QALY gained / DALY averted in populations with 
lower baseline health. As health, and possibly even health literacy increase, so too will the 
setting-specific WTP thresholds.
The WHO advocates decision criteria based on regional gross domestic product (GDP) as an 
alternative to WTP thresholds. According to the CHOICE guidelines (CHOosing 
Interventions that are Cost-Effective), there are three categories of cost-effectiveness based 
on GDP: highly cost-effective are interventions that cost less than per capita GDP; cost-
effective are interventions that are between one and three times per capita GDP; and 
interventions that cost more than three times per capita GDP are not considered cost-
effective (WHO, 2005). This method is based in economic definitions of regional 
affordability, defining ceiling ICERs according to national productivity. However, the 
approach may violate notions of equity and ignore valuable contributions individuals make 
beyond livelihood.
GDP estimates from resource-limited settings are notoriously inaccurate, due primarily to 
the challenges of unrecorded economic activity and economic instability that may selectively 
inhibit production of goods and services, driving down GDP approximations (Jerven, 2013). 
Use of GDP thresholds may mask intra-region variation. The WHO region classification that 
groups countries based on estimates of burden of disease may not capture all relevant 
country-level realities, generating state-specific cost-effectiveness ceiling ratios that ignore 
variation between countries within a given WHO region, and fortifying inequalities in health 
between nearby but financially diverse settings. For example, per capita GDP in South 
Africa is estimated as 11,300 US dollars compared to 900 US dollars in nearby Malawi (The 
World Factbook, 2013); however, both are within WHO African region E, with an associated 
per capita GDP threshold of $2,154. In practice, regional GDP estimates may conceal 
country-specific economic complexities, and may create an artificially high (or artificially 
low) threshold for acceptability (Jerven, 2013). Ultimately, the approach may undercut 
access to interventions for economically unstable regions where GDP is unpredictable and 
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may be measured as artificially low. Comparing new interventions to already accepted 
interventions may be a more acceptable approach than the GDP comparison. However, this 
too is problematic as the choice of comparators can influence whether a program appears 
cost-effective or not (Johannesson & Meltzer, 1998).
Even regionally-adjusted GDP estimates ignore the role that external donors play in driving 
health programming implementation (Shiffman, 2006). Health programs and interventions in 
resource-limited settings are frequently sponsored by donor agencies with their own disease- 
or population-specific objectives (Kapiriri et al., 2004; Kapiriri & Norheim, 2004; Kapiriri, 
Robberstad, & Frithjof Norheim, 2003; Lasry, Carter, & Zaric, 2011; Reichenbach, 2002). 
For example, from 2003 through 2012, the Global Fund disbursed nearly $550 million to 
Malawi for HIV-related activities (Global Fund Disbursements by Region, Country and 
Grant Agreement (in USD equivalents), 2012). This enormous influx of funds earmarked for 
HIV creates two parallel systems that Ministry of Health officials need to evaluate – HIV-
related interventions and non-HIV related interventions. Cost-effectiveness thresholds that 
fail to consider the role of donors create a false paradigm for evaluating and comparing 
interventions. The role of external donors is also relevant when considering the decision-
making autonomy. For example, money reserved for HIV prevention efforts cannot be spent 
on unrelated health programs even if they are evaluated as being more cost-effective. 
Relevant to earlier arguments regarding ethical challenges of CEA-focused decisions, 
earmarked funds may or may not adhere to the ethical principles of prioritizing the severely 
ill. It is important to consider spending restrictions, be they due to budget constraints or 
donor agencies, when evaluating the utility of CEAs and how they influence resource 
allocation in resource-limited settings.
Interpreting CEA outcomes in resource-limited settings - proposed 
solutions to inequity
As CEA studies gain traction in driving resource-allocation and priority setting in resource-
limited settings, a thorough evaluation of the ethical implications of how these model 
outcomes are interpreted is warranted (Jamison, Breman, ARMeasham, et al., 2006; Making 
choices in health: WHO Guide to Cost-effectiveness Analysis, 2003; WHO, 2005). We have 
explored concerns of distributive justice and equity that may be imperfectly captured in CEA 
outcomes. We also considered how CEA thresholds create controversial cutoffs that may not 
account for the economic and funding environment in which resource-allocation decisions 
are made in resource-limited settings. Issues including maximum attainable health, the 
limited applicability of utility values of health established in resource-rich settings or the 
debated universality of disability weights, and the role of external donors in driving funding 
allocation are a few of the elements that complicate interpretation of CEA outcomes in 
resource-limited settings.
The relevance of CEAs in contributing to resource-allocation decisions may hinge on 
explicitly integrating equity concerns into the methods, associated outcomes, and the 
ultimate decision to implement an intervention (Sassi, Archard, & Le Grand, 2001). 
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Researchers have proposed several methodological approaches to incorporate societal 
considerations of equity and other ethical shortcomings into CEAs.
1. Cost Value Analysis
Finally, cost value analysis adjusts results from cost-effectiveness analyses to reflect society-
specific degrees of concern for prioritization of disability or disease severity (Nord, 2015). 
In a QALY-based analysis this is done by compressing mild to moderate utility states 
towards the upper end of the utility scale such that individual gains for the sick are preferred 
over gains for the comparatively healthy. This methodology could be applied to DALY-based 
analyses for application in resource-limited settings by compressing disability weights at the 
lower end of the scale to overvalue the aversion of more severe disability. A setting-specific 
severity gradient adjustment can generate a graded willingness to pay per QALY or DALY 
that may better represent distinct socio-political priorities.
2. Equity Weights and Social Welfare Function
Severity preferences and health-potential considerations may be addressed in CEAs by the 
use of equity weights and social welfare functions (Nord et al 1999, Pinkerton 2002) 
(Bleichrodt, 1997; Ubel et al., 2000). In this approach, researchers must analyze the strength 
of a society’s preference for health equity to inform weighting of interventions that benefit 
particular groups over others (Dolan, 1998; Wagstaff, 1991). There is no consensus 
regarding which distribution concerns should be incorporated into health intervention 
prioritization (Bobinac et al., 2012). The Guidance for Priority Setting in Health Care (GPS-
Health) proposes a checklist of criteria to be considered for equitable priority setting of 
interventions that aim to maximize health, minimize inequities, and protect against 
prohibitive costs of illness including: severity of disease, realization of potential, past health 
loss, socioeconomic status, geographical area of living, gender, race, ethnicity, religion, 
sexual orientation, economic productivity, care for others, and catastrophic health 
expenditures (Norheim et al., 2014). Unfortunately, it is difficult to elicit stable preferences, 
complicating implementation of equity-weighted QALYs or DALYs for inclusion in CEAs 
(Johri & Norheim, 2012).
3. Mathematical Modeling
Mathematical programming can compare opportunity costs associated with alternative 
policies and health interventions/programs (Cleary, Mooney, & McIntyre, 2010). The goal of 
this methodology is to maximize health gains while incorporating equity constraints that can 
ensure prioritization of specific populations. While attempting to represent the equity/
efficiency tradeoffs associated with alternative health resource allocation options to optimize 
equity and efficiency, such modeling is limited by the challenges in quantifying the 
opportunity costs associated with competing equity constraints. Quantifying these costs will 
be critical to future research efforts, and is addressed in part by the rank-ordered approach of 
multi-criteria decision analysis.
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4. Multi-Criteria Decision Analysis
Multi-criteria decision analysis may be a promising approach to quantify and weight 
potentially competing priorities of efficiency (i.e., cost-effectiveness) and equity (Baltussen 
& Niessen, 2006; Baltussen et al., 2006; Johri & Norheim, 2012). This method overlays a 
conceptual framework on complex decisions as a means to establish preferences between 
options, applying criteria for priority setting based on individual preferences. By doing so, 
multi-criteria decision analysis tools explicitly consider local values and judgments, creating 
a rank-ordering of program priorities. Multi-criteria decision analysis and formal economic 
evaluations using ICERs are distinct from one another in that multi-criteria decision analysis 
incorporates mathematical modeling of existing evidence that devises priority setting and 
weights with consideration of opportunity costs and recognition of fixed budgets, through 
techniques such as program budgeting and marginal analysis (Thokala, 2011). Multi-criteria 
decision analysis has been used successfully in the health resource allocation process of 
resource-limited settings (Jehu-Appiah et al., 2008). However, there are important 
limitations to multi-criteria decision analysis, most notably that the preference ranking 
method may not address the feasibility or complexity of a given intervention. To date, 
evaluations of multi-decision criteria have focused on elements that are amenable to 
quantification, including cost-effectiveness and disease severity (Baltussen et al., 2006; 
Jehu-Appiah et al., 2008).
The objective of these approaches is to rectify the disconnect between CEA outcomes and 
societal preferences by combining the complexity of implicit decision criteria (i.e. values of 
equity and distributive justice) with the concrete health status and cost criteria of CEA 
models. In the absence of universal utility or disability weights or severity adjustment 
factors, researchers and policymakers can employ these methods to generate setting-specific 
interpretations of cost-effectiveness results, informing difficult resource allocation decisions. 
Unfortunately, adjusting for equity in a utilitarian model by applying weights to one 
individual or group will unavoidably detract from another; existing methodological 
accommodations do not account for the opportunity costs associated with resource allocation 
in the context of finite funds. Explicitly addressing these tradeoffs will be a critical next step 
in CEA design and outcome evaluation. One objective of future research should focus on 
end-user application of CEA outcomes – adapting the often-sought universality of models to 
permit utilization by policy makers. Next steps for equity weights may include an extension 
of GPS that considers the health disability as well as the system- and population-specific 
priorities in terms of disease burden and the characteristics of the social groups that a given 
intervention targets (Norheim et al., 2014). Eventually, these priorities could be assigned 
weights based on a given community or country’s a priori values, with subsequent 
integration into models. Multi-criteria decision analyses may establish tools that translate 
CEA outcomes to robust estimates of costs and coverage to establish scalability and 
feasibility of the rank-ordered cost-effective interventions. Ultimately, these methodological 
advances could permit intervention implementation – transforming the desirable “universal” 
CEA outcomes that focus on comparability and uniformity, to setting-specific appropriate 
applications.
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The ethical implications of CEAs in resource-limited settings are vast. While many 
considerations may overlap with resource-rich settings, ethical shortcomings of CEAs 
particular to more resource-limited settings and the methodological interventions needed to 
address them require ongoing discussion. Although only one component of a larger, more 
complex decision-making process, CEAs stand to influence the distribution of healthcare 
resources that directly influence morbidity and mortality for the world’s most vulnerable 
populations. Alongside cost-effectiveness, considerations of equity, feasibility, and 
affordability are all essential dimensions of the resource-allocation decision making process 
(Johri & Norheim, 2012). CEAs stand to make meaningful contributions to the much-needed 
efficiency gains in healthcare. However, communities will incur substantial, albeit hidden, 
costs if policymakers and researchers fail to consider the economic and societal 
ramifications associated with allocating scarce resources in a manner that does not reflect 
the ethics and priorities of implementing partners.
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